COVID-19: A Serious Warning for Emergency Health Innovation

Authors

  • Kun Harismah Department of Chemical Engineering, Faculty of Engineering, Universitas Muhammadiyah Surakarta, Surakarta, Indonesia
  • Mahmoud Mirzaei Department of Biomaterials, Nanotechnology and Tissue Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

DOI:

https://doi.org/10.22034/AJSE.2012032

Keywords:

Corona, COVID-19, Medication

Abstract

COronaVIrus Disease 2019 (COVID-2019), has been first recognized in China in late 2019 but it has been very soon spread all over the world as a global pandemic crisis. From November 2019 until June 2020, around 6 million people have been recognized to be suffered by COVID-19; some of them died unfortunately, some of them recovered happily, and so many of them are still under treatments. Although it is supposed that COVID-19 has been caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the available treatments are not still sufficient enough for employing neither therapeutics nor prevention processes. This trend means than the conventional science, research and technology is not sufficient any more for dealing with the crises of nowadays life, as COVID-19 could STOP the regular life of the world. Therefore, COVID-19 is almost a serious warning for emergency health innovation, to find all the required materials as soon as possible in the time of such global crises. So, despite the expertise and specific major of research, let’s think how to deal with the global health crises such as COVID-19 and notice its serious waning of emergency health innovations employing the NBICA convergence approaches.

References

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil. Med. Res. 2020;7:1-10.

Worldometers.info. Dover, Delaware, U.S.A. Publishing Date: 1 June, 2020.

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agent. 2020:105924.

Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J. Clin. Microbiol. 2020;58: in press.

Harismah K, Mirzaei M. Favipiravir: Structural Analysis and Activity against COVID-19. Adv. J. Chem. B 2020;2:55-60.

Mirzaei M, Harismah K, Da'i M, Salarrezaei E, Roshandel Z. Screening efficacy of available HIV protease inhibitors on COVID-19 protease. J. Mil. Med. 2020;22:100-107

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-1034.

Mirzaei M. Science and engineering in silico. Adv. J. Sci. Eng. 2020;1:1-2.

Mirzaei, M. Lab-in-Silico insights. Adv. J. Chem. B 2020;2:1-2.

Mirzaei, M. Drug discovery: a non-expiring process. Adv. J. Chem. B 2020;2:46-47.

Khushf G. The ethics of NBIC convergence. J. Med. Phil. 2007;32:185-196.

Collins FS, Varmus H. A new initiative on precision medicine. New Engl. J. Med. 2015;372:793-795.

Downloads

Published

2020-06-30

How to Cite

Harismah, K., & Mirzaei, M. (2020). COVID-19: A Serious Warning for Emergency Health Innovation. Advanced Journal of Science and Engineering, 1(2), 32–33. https://doi.org/10.22034/AJSE.2012032

Issue

Section

Editorial